Download PDF
Thromb Haemost 1984; 51(01): 012-015
DOI: 10.1055/s-0038-1660998
Original Article
Schattauer GmbH Stuttgart

Heparin Small Pool High Yield Purified Factor VIII: In Vivo Recovery and Half-Life of Routinely Produced Freeze-Dried Concentrate

C T Smit Sibinga
1   The Red Cross Blood Bank Groningen-Drenthe, Groningen, The Netherlands
,
S M G J Daenen
2   The Division of Haematology, Department of Internal Medicine, University Hospital, Groningen, The Netherlands
,
G W van Imhoff
2   The Division of Haematology, Department of Internal Medicine, University Hospital, Groningen, The Netherlands
,
A Maas
1   The Red Cross Blood Bank Groningen-Drenthe, Groningen, The Netherlands
,
P C Das
1   The Red Cross Blood Bank Groningen-Drenthe, Groningen, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 15 August 1983

Accepted 01 November 1983

Publication Date:
19 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

New approaches and techniques for improving source material collection and Factor VIII production at Blood Bank level have been reported recently.

Heparin has been shown to be of importance in increasing yields and stability of FVIII in the purification and concentration process. Work has been done to develop on a routine scale the heparin double cold precipitation technique for the production of a freeze-dried high yield purified FVIII concentrate.

The product has been tested clinically in 4 severe hemophilia A patients for recovery, half-life and acute side-effects, using two dosages over 8 infusions. There was no significant difference between the two dosages. Mean recovery 99.1% and mean halflife 8 hr, ranging from 6.5 to 10.3 hr.

No side-effects were observed.

These results justify further exploration of the potential of heparin for high yield purified FVIII production.

Key Words

Heparin/factor VIII - Purified factor VIII - T½ factor VIII - Cryopreserved factor VIII - Small pool factor VIII
 

  • References

  • 1 Pool JG, Shannon AE. Production of high-potency concentrate of antihaemophilic globulin in a closed-bag system. N Engl J Med 1965; 273: 1443-1447
    CrossrefPubMedGoogle Scholar
  • 2 Morrison PR, Edsall JT, Miller SG. Preparation and properties of serum and plasma proteins. XVIII The separation of purified fibrinogen from fraction I of human plasma. J Am Chem Soc 1948; 70: 3103-3108
    CrossrefPubMedGoogle Scholar
  • 3 Mason FC. The thaw-siphoning technique for production of cryo-precipitate concentrate of Factor VIII. Lancet 1978; 2: 15-17
    PubMedGoogle Scholar
  • 4 Das PC, Smit Sibinga CTh. Thaw-siphon technique for Factor VIII. cryoprecipitate. Lancet 1978; 2: 273
    PubMedGoogle Scholar
  • 5 Das PC, Smit Sibinga CTh. Haemophilia and future: better cryo for more concentrate. In: Smit Sibinga CTh. (ed) Home-treatment for haemophilia: perspectives and limitations. Groningen: Drukkerij Schut; 1980. pp 57-65
    Google Scholar
  • 6 Prowse CV, McGill A. Evaluation of the “Mason” (continuous-thaw- siphon) method for cryoprecipitate production. Vox Sang 1979; 37: 235-243
    PubMedGoogle Scholar
  • 7 Foster PR, Dickson AJ, McQuilan TA, Dickson IH, Keddie S, Watt JG. Control of large-scale plasma thawing for recovery of cryoprecipitate Factor VIII. Vox Sang 1982; 42: 180-189
    CrossrefPubMedGoogle Scholar
  • 8 Rock GA, Cruickshank WM, Thackaberry ES, Palmer DS. Improved yields of Factor VIII from heparinized plasma. Vox Sang 1979; 36: 294-300
    CrossrefPubMedGoogle Scholar
  • 9 Rock GA. The effects of heparin on Factor VIII recoveries: markedly improved yields. In: Smit Sibinga CTh, Das PC, van Loghem JJ. (eds) Bloodtransfusion and problems of bleeding. The Hague: Martinus Nijhoff Publishers; 1982. pp 273-277
    Google Scholar
  • 10 Rock GA, Palmer DS. The role of calcium, thrombin and other proteolytic enzymes in Factor VIII degradation. Transfusion 1980; 20: 652 (Abst.)
    PubMedGoogle Scholar
  • 11 Rock GA, Palmer DS. Intermediate purity Factor VIII production utilizing a cold insoluble globulin technique. Thromb Res 1980; 18: 551-556
    CrossrefPubMedGoogle Scholar
  • 12 Smit Sibinga CTh, Welbergen H, Das PC, Griffin B. High yield method of production of freeze-dried purified Factor VIII by Blood Banks. Lancet 1981; 2: 449-450
    PubMedGoogle Scholar
  • 13 Welbergen H, Das PC, Smit Sibinga CTh. Purified Factor VIII: a high yield production method for routine Blood Banks. In: Smit Sibinga CTh, Das PC, van Loghem JJ. (eds) Bloodtransfusion and problems of bleeding. The Hague: Martinus Nijhoff Publishers; 1982. pp 265-271
    Google Scholar
  • 14 Development systems for efficient separation of Factor VIII from human fresh frozen plasma. Lane RS, Rock GA, Smit Sibinga CTh. (eds) Groningen: Red Cross Blood Bank Groningen-Drenthe; 1982
  • 15 Welbergen H. Possibilities and limitations for routine production of a high recovery intermediate purity Factor VIII concentrate in a regional Blood Bank. Groningen: Red Cross Blood Bank Groningen- Drenthe: 1981
    Google Scholar
  • 16 Evers A, Koopman-Giesen A. High yield method of freeze-dried Factor VIII. A pharmacopoeial study on the implementation of the method for routine production at Blood Bank level. Groningen: Red Cross Blood Bank Groningen-Drenthe; 1982
    Google Scholar
  • 17 WHO Technical report series 626; Geneva: 1978
  • 18 Allain JP, Verroust F, Soulier JP. In vitro and vivo characterization of Factor VIII preparations. Vox Sang 1980; 38: 68-80
    CrossrefPubMedGoogle Scholar
  • 19 International Forum. What is the importance of the “small pool concept” in the preparation of fraction I and cryoprecipitates for the prevention of post-transfusion hepatitis. Vox Sang 1980; 38: 106-119
    CrossrefPubMedGoogle Scholar